SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

Author's Avatar
Aug 15, 2018
Article's Main Image

­­Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018

Development of ibrexafungerp intravenous (IV) formulation delayed

Continued progress in our strategy to expand the use of oral ibrexafungerp in multiple indications

Adequate funds to support operations into 2020

PR Newswire